Press releases for 2006
Our press releases for 2006 are available below.
(Please note: Adobe
Acrobat Reader is required to view these files)
24 August 2006
Cambridge Laboratories, the specialist pharmaceuticals company, today announces that its partner, OPi SA, has launched XENAZINE® 25mg (tetrabenazine) in France
28 June 2006
Cambridge Laboratories appoints Dr John Padfield as Chairman of the Board of Directors
24 May 2006
Cambridge Laboratories signs exclusive marketing agreement for NITOMAN® (Tetrabenazine) with Temmler Pharma in Germany and Austria
04 May 2006
Cambridge Laboratories Announces European Union Marketing Authorisation for Biosimilar Recombinant Human Growth Hormone – Valtropin®
03 April 2006
Cambridge Laboratories’ XENAZINE® (Tetrabenazine) Receives FDA Approvable Letter for Treatment of Chorea Associated with Huntington’s disease
24 February 2006
Cambridge Laboratories Announces CHMP Positive Opinion for Biosimilar Recombinant Human Growth Hormone – ValtropinTM
15 February 2006
Study published in Neurology shows Xenazine® (Tetrabenazine) significantly improves debilitating movement disorder caused by Huntington's Disease
18 January 2006
Cambridge Laboratories supports key science and medical research in the North East